Ibogaine is an indole alkaloid that acts simultaneously on multiple neurotransmitter systems: serotonin (5-HT2A/2C), dopamine (D2), opioid (mu, kappa, delta), NMDA, sigma-2, and nicotinic acetylcholine receptors. This multi-target profile produces a comprehensive neurochemical reset rather than modulating a single pathway.
Crucially, ibogaine upregulates Glial Cell Line-Derived Neurotrophic Factor (GDNF) and Brain-Derived Neurotrophic Factor (BDNF), promoting lasting neuroplasticity. Its primary metabolite, noribogaine, remains active for weeks post-treatment, sustaining serotonin reuptake inhibition and mood stabilization during the critical integration window.
The ibogaine experience includes a 12 to 24 hour introspective phase during which patients process the psychological roots of their depression, trauma, or addiction. Patients at MindScape Retreat under Dr. Omar Calderon, M.D., consistently describe this as confronting and resolving patterns that years of conventional therapy never reached.
Ketamine is an NMDA receptor antagonist that produces rapid antidepressant effects by blocking glutamate signaling, triggering a compensatory glutamate surge that temporarily enhances synaptic connectivity. The FDA-approved nasal spray esketamine (Spravato) is the S-enantiomer of ketamine, marketed for treatment-resistant depression.
Ketamine produces measurable mood improvement within hours, making it valuable for acute suicidal ideation. However, these effects are transient, typically lasting 3 to 14 days before fading. This necessitates repeated infusions: standard protocols call for 6 initial sessions over 2 to 3 weeks, followed by monthly or biweekly maintenance infusions indefinitely.
As a Schedule III controlled substance, ketamine carries abuse potential. The dissociative experience during infusion is described as a detached, dreamlike state but lacks the directed introspective depth reported with ibogaine. Ketamine does not address the psychological or neurobiological root causes of depression or addiction.
| Factor | Ibogaine (MindScape) | Ketamine / Esketamine |
|---|---|---|
| Mechanism | Multi-receptor reset: serotonin, dopamine, opioid, NMDA, sigma-2, GDNF | Primarily NMDA receptor antagonism + glutamate surge |
| Treatment sessions | Single 24 to 36 hour session | 6 initial infusions + monthly maintenance indefinitely |
| Duration of effect | Months to years from single treatment | 3 to 14 days per infusion, effects fade |
| Addresses root cause | Yes: neurochemical reset + deep psychological processing | No: symptom suppression without addressing underlying drivers |
| Addiction treatment | Primary indication, eliminates withdrawal + cravings | Not indicated for addiction; carries abuse potential |
| Abuse potential | None: not rewarding at therapeutic doses | Schedule III controlled substance, dissociative effects |
| Neuroplasticity | GDNF + BDNF upregulation, sustained for weeks via noribogaine | BDNF increase, short-lived |
| Psychological depth | Profound introspective experience addressing trauma and patterns | Dissociative state, limited introspective content |
| Medical supervision | Yes: EKG, cardiac monitoring, 24hr clinical team | Yes: vital signs during 40-minute infusion |
| FDA status (US) | Not FDA-approved; legal in Mexico at licensed clinics | FDA-approved (esketamine nasal spray for TRD) |
| Cost (first year) | Single investment: $7,500 to $12,000 all-inclusive | Initial: $2,400 to $4,800 + maintenance: $4,800 to $9,600/yr |
| Cost (lifetime) | Same single investment, no ongoing cost | Cumulative: $10,000+ per year, indefinitely |
Ketamine is valuable for acute crises, particularly suicidal ideation, where its rapid onset (hours) can be life-saving. However, its antidepressant effect is a neurochemical bandage: it temporarily restores synaptic connectivity without addressing the underlying drivers of depression.
Ibogaine addresses depression at multiple levels simultaneously. Neurochemically, it resets serotonin, dopamine, and opioid receptor sensitivity. Psychologically, the introspective experience surfaces and resolves the trauma, grief, and cognitive patterns sustaining the depressive state.
A growing number of patients arrive at MindScape after ketamine infusions lost effectiveness. This is expected: ketamine's mechanism produces tolerance, and its single-pathway approach cannot address the multi-factorial nature of chronic depression.
Ketamine is not an addiction treatment. It carries its own abuse potential as a Schedule III controlled substance and has no clinically validated mechanism for interrupting substance dependence. Some experimental protocols have explored ketamine for alcohol use disorder, but results are modest and require repeated administration.
Ibogaine, by contrast, is primarily known for its ability to interrupt opioid addiction. At the opioid receptor level, ibogaine and noribogaine modulate receptor sensitivity without activating the reward cascade. Acute opioid withdrawal is eliminated within hours. Psychological cravings are addressed through the introspective experience. The neuroplasticity window enables patients to build new patterns during the critical early recovery period.
Ibogaine eliminates acute opioid withdrawal in hours and interrupts craving at the neurochemical level. No ketamine equivalent exists for this indication.
Ibogaine's introspective depth allows processing of traumatic memories in ways ketamine's dissociative state does not facilitate. Stanford research shows 88% PTSD reduction in veterans.
Depression co-occurring with addiction requires treatment that addresses both simultaneously. Ibogaine's multi-receptor mechanism is uniquely suited to dual diagnosis patients.
Patients tapering from SSRIs who experience debilitating withdrawal may benefit from ibogaine's serotonergic reset. This requires careful medical management of the taper timeline.
Ketamine clinics price individual infusions at $400 to $800. Standard protocols require 6 initial sessions ($2,400 to $4,800) followed by maintenance infusions every 2 to 4 weeks. Over one year, maintenance alone costs $4,800 to $9,600. Over five years, a ketamine patient may spend $25,000 to $50,000 — with effects that fade if infusions stop.
MindScape Retreat's ibogaine treatment is a single all-inclusive investment of $7,500 to $12,000 covering accommodations, all meals, medical evaluations, the ibogaine session itself, supplementary therapies (NAD+, psilocybin, 5-MeO-DMT options), and 90-day post-treatment integration support. There are no recurring costs.
For patients whose depression or addiction has failed to respond to ketamine, SSRIs, or conventional treatment, ibogaine represents not just a clinical alternative but a fundamentally different economic proposition: a single investment that addresses root causes rather than an open-ended subscription to symptom management.
"I see patients every month who have spent thousands on ketamine infusions that stopped working after 6 months. They come to MindScape expecting another temporary fix and leave with something they have never experienced: lasting freedom from the neurochemical patterns driving their depression. Ibogaine is not a better version of ketamine. It is a fundamentally different category of treatment."
— Dr. Omar Calderon, M.D., Clinical Director, MindScape Retreat
Whether you are considering ibogaine for the first time or have tried ketamine without lasting results, our admissions team will review your history and help determine if ibogaine is the right path. All consultations are confidential.